Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Mundipharma

This page shows the latest Mundipharma news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz

Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz

GlobalData predicts Trazimera can earn $9m in its first year, far behind the forecast 12 month totals for Celltrion and Mundipharma’s Herzuma ($59m), Amgen’s Kanjinti ($33m), and Samsung Bioepsis

Latest news

More from news
Approximately 9 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Finally it is always encouraging to see medium size companies like Mundipharma and Jazz finding and licensing new product opportunities. ... Mundipharma built its oncology franchise following the acquisition of an old anti-cancer drug and the deal to

  • When science is not enough When science is not enough

    Mundipharma’s Will Dunlop on a new framework to guide development programmes to a better destination. ... programme,” says Will Dunlop, head of market access for Mundipharma International, who has been developing the project over the last five years.

  • Deal Watch October 2016 Deal Watch October 2016

    For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Divestment of US rights. 1, 050. Esteve/ Mundipharma. Discovery and development of next generation pain products including E-52862 in P2 for neuropathic pain.

More from intelligence
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest appointments

  • New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics

    Latest movers in pharma. Mundipharma hires new SVP business development and strategic partnerships. ... Mundipharma has named Marco Cerato as its senior vice president, business development and strategic partnerships.

  • Mundipharma appoints Dr Alberto Martinez as president and CEO Mundipharma appoints Dr Alberto Martinez as president and CEO

    His new role will see him take responsibility for strengthening Mundipharma’s network in Europe and focus on its alliances. ... Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.

  • Mundipharma appoints chief information officer Mundipharma appoints chief information officer

    His new role will see him take responsibility for the IT services provided to Mundipharma’s global network of associated companies. ... My goal is to ensure that the Mundipharma network has the technology support it needs to lead the charge in pharma

  • Hywel Day joins Napp Pharmaceuticals Hywel Day joins Napp Pharmaceuticals

    Moves from Mundipharma to take up managing director role. Napp Pharmaceuticals has appointed Hywel Day as its new managing director. ... It’s a return to Napp for Day, who spent 10 years at Napp from 2003, before moving to Mundipharma.

  • Napp names new managing director Napp names new managing director

    Alberto Martinez joins from Mundipharma. UK-based Napp Pharmaceuticals has appointed Alberto Martinez as the company's new managing director. ... Martinez's previous experience includes time as marketing manager at Mundipharma's international operations

More from appointments
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Quick links

Infographics

Multimedia